Novo Nordisk (NYSE: NVO) has continued its ongoing share repurchase programme, accumulating a total of 23,090,000 B shares under the initiative launched on 6 May 2026.

The repurchase programme operates in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council, as well as the Commission Delegated Regulation (EU) 2016/1052, known as the Safe Harbour Rules.

The broader programme targets up to DKK 15 billion in B share repurchases over a 12-month period beginning 4 February 2026, reflecting the company’s commitment to returning capital to shareholders.

Under the specific programme initiated on 6 May 2026, Novo Nordisk is authorized to repurchase B shares worth up to DKK 11,200,000,010.45 through 1 February 2027.

Between 5 and 9 October 2026, the company executed daily purchases of approximately 245,000 to 250,000 B shares, with average purchase prices ranging from DKK 246.39 to DKK 254.93 per share.

The five trading sessions between 5 and 9 October added a combined transaction value of roughly DKK 311.6 million to the programme’s accumulated total.

As of 9 October 2026, the accumulated transaction value under the current programme reached DKK 6,758,876,433, covering 23,090,000 B shares in total.

Since the broader programme began on 4 February 2026, Novo Nordisk has repurchased a total of 37,849,179 B shares at an average price of DKK 278.97, representing a total transaction value of DKK 10,558,876,422.

Novo Nordisk now holds 51,889,876 B shares as treasury shares, each with a nominal value of DKK 0.10, corresponding to 1.2% of the company’s total share capital.

The total number of A and B shares outstanding, including treasury shares, stands at 4,465,000,000, reflecting the full scope of the Danish pharmaceutical giant’s equity structure.

Novo Nordisk employs over 67,000 people globally and operates across research, development, and commercial healthcare functions, with a stated mission to drive change for lasting health.

The company’s B shares are listed on Nasdaq Copenhagen under the ticker Novo-B, while its American Depositary Receipts trade on the New York Stock Exchange under the symbol NVO.

Full transaction details for each individual repurchase made under the programme are published and publicly accessible on novonordisk.com.